This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (54)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

L. E. ROSENBLUM, M.D.; R. J. KORN, M.D.; HYMAN J. ZIMMERMAN, M.D.

AMA Arch Intern Med. 1960;105(4):583-593.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Iproniazid, an amine oxidase inhibitor, originally was tested for its antituberculous properties. When its toxicity appeared to be greater than that of isoniazid, it was abandoned as an antituberculous agent. During this trial period euphoria, increased nervous system activity, and less mental depression were frequently observed. These effects have led to its extensive use in mental illness. Iproniazid has also been suggested for the treatment of rheumatoid arthritis and spondylitis,^1,2 intractable angina pectoris,^3-5 far-advanced metastatic carcinoma,⁶ and nontuberculous bone and joint infections.⁷

Minor side-effects of the drug, including neurologic ^3,4,8,9 gastrointestinal,^3,8 and genitourinary symptoms,^3,8,9 have been reported. These usually have disappeared promptly with the discontinuance of the drug or with reduction of the dose.

A more serious, although infrequent, complication of iproniazid therapy is jaundice. The present report is an analysis of 90 patients who developed jaundice associated with the administration of the drug.

Materials and Methods

The records (or abstracts . . . [Full Text PDF of this Article]

Author Affiliations
Chicago

Fellow in Medicine, Mount Sinai Hospital, and Instructor in Medicine, The Chicago Medical School (Dr. Rosenblum); Chief, Medical Service, Veterans Administration West Side Hospital, and Clinical Assistant Professor of Medicine, University of Illinois College of Medicine (Dr. Korn); Professor and Chairman, Department of Medicine, The Chicago Medical School, and Chairman, Department of Medicine, Mount Sinai Hospital (Dr. Zimmerman).

Footnotes
Submitted for publication June 16, 1959.

Iproniazid used as Marsilid (Hoffman-La Roche, Inc.).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?